BackGreat Novel Therapeutics Biotech & Medicals Overview

Great Novel Therapeutics Biotech & Medicals Accounts Payable

Track Great Novel Therapeutics Biotech & Medicals's accounts payable ($5.1M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$5.11M

Peer trimmed avg / median

Loading

Great Novel Therapeutics Biotech & Medicals Accounts Payable History

Loading

Great Novel Therapeutics Biotech & Medicals vs. peers: Accounts Payable Comparison

Loading

Great Novel Therapeutics Biotech & Medicals Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Great Novel Therapeutics Biotech & Medicals (7427.TWO) FAQ

As of the most recent data (June 2026), 7427.TWO shows a accounts payable of $5.1M. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 7427.TWO's accounts payable is now $5.1M (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Great Novel Therapeutics Biotech & Medicals is outperforming or lagging.

Tracking 7427.TWO's accounts payable over time shows whether Great Novel Therapeutics Biotech & Medicals is scaling, shrinking, or reshaping that part of the business. The current reading is $5.1M In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Great Novel Therapeutics Biotech & Medicals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $5.1M) with ownership activity and broader fundamentals.

Great Novel Therapeutics Biotech & Medicals's accounts payable is $5.1M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.